Open AccessElevated lipoxygenase and cytochrome P450 products predict progression of chronic kidney disease
Author(s) -
Farsad Afshinnia,
Lixia Zeng,
Jaeman Byun,
Stefanie Wernisch,
Rajat Deo,
Jing Chen,
L. Lee Hamm,
Edgar R. Miller,
Eugene P. Rhee,
Michael J. Fischer,
Kumar Sharma,
Harold I. Feldman,
George Michailidis,
Subramaniam Pennathur,
Lawrence J. Appel,
Alan S. Go,
Jiang He,
John W. Kusek,
James P. Lash,
Panduranga S. Rao,
Mahboob Rahman,
Raymond R. Townsend
Publication year - 2018
Publication title -
nephrology, dialysis, transplantation/nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfy232
Subject(s) - medicine , kidney disease , interquartile range , odds ratio , confidence interval , cohort , endocrinology , clinical significance , biomarker , gastroenterology , biology , biochemistry
The clinical relevance of arachidonic acid (AA) metabolites in chronic kidney disease (CKD) progression is poorly understood. We aimed to compare the concentrations of 85 enzymatic pathway products of AA metabolism in patients with CKD who progressed to end-stage kidney disease (ESKD) versus patients who did not in a subcohort of Chronic Renal Insufficiency Cohort (CRIC) and to estimate the risk of CKD progression and major cardiovascular events by levels of AA metabolites and their link to enzymatic metabolic pathways.